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A B S T R A C T
We report two individual cases of cardio-facio-cutaneous (CFC) syndrome with severe neurological
impairment consisting of infantile spasms with hypsarrhythmia and refractory epilepsy with multifocal
epileptic paroxysms such as modiﬁed hypsarrhythmia. Both cases shared diffuse brain atrophy and
severely delayed myelination on neuroimaging. Genetic analysis revealed individual heterozygous
mutations in the KRAS (phenotype of CFC/Noonan syndrome) and BRAF genes (phenotype of CFC
syndrome). Neurological impairment in cases with mutations in the RAS/MAPK (mitogen activated
protein kinase) signal pathway may be more severe, and could be linked to some forms of refractory
epilepsy, especially epileptic encephalopathy that includes infantile spasms.
 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.1. Introduction
Cardio-facio-cutaneous (CFC) syndrome is a very rare and
sporadic disease that includes the characteristics of dysmorphic
facial appearance, ectodermal abnormalities, cardiac abnormalities,
growth retardation and neuro-developmental delay. This syndrome
is categorized as one of the RAS/MAPK syndromes, which cause
altered signal transduction of the RAS/MAPK (mitogen activated
protein kinase) pathway, including BRAF, MEK1/2, and KRAS.1–3
Compared with other RAS/MAPK syndromes, such as Costello
syndrome and Noonan syndrome, CFC syndrome exhibits a more
severe phenotype including severe neurological impairment,
seizures, and developmental delay. We describe the clinical details
of neurological ﬁndings in two cases of genetically determined CFC
syndrome which displayed refractory epilepsies diagnosed as
infantile spasms and other epileptic encephalopathy, and we then
compare our results with those of similar literature ﬁndings.
2. Case reports
2.1. Case 1: six-year-old boy
A large-for-date boy was delivered as the ﬁrst child to healthy
and non-consanguineous Japanese parents (mother 42 years old
and father 31 years old) at 32 weeks of gestational age with a birth
weight of 3758 g and with moderate neonatal asphyxia (an Apgar* Corresponding author. Tel.: +81 79 432 3531; fax: +81 79 432 3672.
E-mail address: ama-p@rc4.so-net.ne.jp (M. Adachi).
1059-1311/$ – see front matter  2011 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2011.07.013score of 6 at 5 min after birth) following a normal pregnancy. The
patient was intensively treated in the neonatal intensive care unit
(NICU) in our hospital. Postnatal screening showed fetal hydrops
with heart failure due to severe pulmonary valve stenosis which
was treated with diuretics and beta blockers. Peculiar craniofacial
features included ‘‘coarse face,’’ curly hair, prominent forehead,
downslanting palpebral ﬁssures, short nose and broad nasal tip
with anteverted nares, low-set dysmorphic and posteriorly
angulated ears, abnormal skin (loose and pigmented skin with
deep furrows and multiple lentigo, wrinkled palms with deep
palmar and plantar creases), webbed neck, chest deformity, and
micromelic dwarﬁsm (Fig. 1A).
At three days postnatal, myoclonic seizures of the extremities
occurred which were controlled by administration of bolus
midazolam (MDL). At the age of 11months, he developed repetitive
series-formed tonic spasms, and the interictal electroencephalo-
gram (EEG) showed hypsarrhythmia (Fig. 1C). Valproic acid (VPA),
clonazepam (CZP), and zonisamide (ZNS) were ineffective in
reducing seizure frequency and improving EEG ﬁndings, and
complete remission was only obtained by one course of low dose
(0.025 mg/kg) adrenocorticotropic hormone (ACTH). Since under-
going ACTH therapy, he has had no episodes of epileptic seizures
while undergoing VPA monotherapy until the present age of six
years, but his most recent (interictal) EEG showed asynchronous,
high-voltage slow waves with irregular spike-waves, or polyspikes
with/without waves dominantly in the right temporal-occipital
region (Fig. 1D).Magnetic resonance imaging (MRI) at three years of
age revealed agenesis of the corpus callosum, ventricular dilatation,
diffuse cortical atrophy and severely delayed myelination (Fig. 1B).
Tracheotomy was performed and persistent mechanical ventilationvier Ltd. All rights reserved.
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Fig. 1. Case 1. ‘‘Coarse face,’’ curly hair, prominent forehead, dysmorphic ears, abnormal loose and pigmented skin, webbed neck, chest deformity, andmicromelic dwarﬁsm at
six years (A), agenesis of the corpus callosum, ventricular dilatation, diffuse cortical atrophy and severely delayed myelination on MRI images at three years (B),
hypsarrhythmia at 11 months (C), asynchronous, high-voltage slow waves with irregular spike-wave or polyspikes with/without waves dominantly in the right temporal-
occipital region at six years of age (D) on EEG.
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Percutaneous endoscopic gastrostomy (PEG) was performed for
repetitive aspiration pneumonia caused by dysphagia. He has been
diagnosed as mentally retarded and had not developed any
expressive language. Additionally, he suffers fromtruncal hypotonia
with increasedmuscle toneand joint contractures inhis extremities.
He has been profoundly delayed in terms of physical and mental
development due to his severe motor and intellectual disabilities.
His karyotype was 46,XY and genetic screening conﬁrmed a
heterozygous nucleotide change within exon 5 of the KRAS gene
(c.458A > T), causing the amino acid substitution D153V, whose
phenotype was CFC/Noonan syndrome.
2.2. Case 2: four-year-old girl
An appropriate-for-date girl (35 weeks of gestational age with a
birth weight of 2624 g) without asphxial episodes was born to
healthy and non-consanguineous parents (mother 30 years old and
father 35 years old) who had previously given birth to three
healthy baby girls. Following delivery, several surface anomalies
were noted, such as an odd-looking ‘‘coarse’’ face (prominent
forehead, short nose and broad nasal bridge with anteverted nares,
downslanting palpebral ﬁssures, and low-set dysmorphic ears),
curly and sparse hair, abnormal skin manifestations (loose,
pigmented skin with multiple lentigo, wrinkled palms with deep
palmar and plantar creases), narrow chest, and hypotonic
micromelic dwarﬁsm (Fig. 2A). Postnatal screening revealed
cardiac failure due to severe hypertrophic cardiomyopathy,
resulting in chronic heart failure, which necessitated the adminis-
tration of diuretics and beta blockers.
Onadmission toourNICU, a subtle seizureoccurredandwasonly
controlled following the infusion of phenobarbital (PB) and MDL.
After this episode, seizures have been severely refractory and
uncontrolled despite the use of a majority of antiepileptic drugs,
including PB, VPA, CZP, ZNS, carbamazepine, phenytoin, primidone,nitrazepam, clobazam, topiramate, lamotirigine, gabapentin, leve-
tiracetam. Seizures are composed of repetitive brief tonic spasms,
tonic-clonic (sometimes developing to status epileptics),myoclonic,
and complex partial seizures (sometimes evolving to generalized
tonic-clonic seizure [GTCS]), all occurring daily and frequently.
Interictal EEG revealed modiﬁed hypsarrhythmia at one year of age
(Fig. 2C), and her most recent (interictal) EEG showed continuous
high-voltage spike orpolyspikeswith/without slowwavesmainly in
the left centro-temporal-parietal regionat four yearsof age (Fig. 2D).
ACTH therapy has not been introduced because ofmoderate cortical
atrophywith delayedmyelination and hypoplastic corpus callosum
on cranialMRI images noted at two years of age (Fig. 2B). In addition
to seizures, she has exhibited frequent involuntary movement,
consisting of dystonia, athetosis, and myoclonus, all resistant to
various muscle-relaxant drugs.
She had frequently developed episodes of dyspnea due to
congenital laryngo/tracheomalacia, which resulted in tracheotomy
and persistent mechanical ventilation during night sleep before
two years of age, but recurrent aspiration pneumonia caused by
dysphagia ﬁnally required PEG. She has been profoundly mentally
retarded and unable to speak anywords. She has been unable to sit
unassisted because of general hypotonia and joint contractures in
her extremities. Overall, she has exhibited severe motor and
intellectual disabilities.
Her karyotype was 46,XX and advanced genetic screening
conﬁrmed a heterozygous nucleotide changewithin exon 12 of the
BRAF gene (c.1454T > C), causing the amino acid substitution
L485S, whose clinical phenotype was CFC syndrome.
3. Discussion
The different types of RAS/MAPK syndrome have many
overlapping characteristics, including craniofacial manifestations,
cardiac malformations, cutaneous, musculoskeletal, gastrointesti-
nal, ocular abnormalities, and neuro-cognitive impairment,
[(Fig._2)TD$FIG]
Fig. 2. Case 2. Odd looking ‘‘coarse’’ face (prominent forehead, short nose, and low-set dysmorphic ears, curly sparse hair), abnormal loose, pigmented skin with multiple
lentigo, narrow chest, and hypotonic micromelic dwarﬁsm at four years (A), diffuse brain atrophy with delayedmyelination and hypoplastic corpus callosum onMRI images
at two years (B), modiﬁed hypsarrhythmia at one year (C), and continous high-voltage spike or polyspikes with/without slowwavesmainly in the left centrotemporalparietal
region at four years of age (D) on EEG.
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signaling in the RAS/MAPK pathway due to mutations mainly in
BRAF, MEK1, or MEK2.1–3 Correlation between conﬁrmed muta-
tions and non-neurological, cardiovascular, cutaneous, and mus-
culoskeletal abnormalities in CFC patients have been discussed,1–3
but detailed analyses of their associated neurological impairments,
especially epileptic conditions, have been sorely lacking.
Only a few previous reports4–10 of CFC syndrome mentioned
associated neurological impairment, especially seizures and EEG
ﬁndings, but were lacking in terms of their detailed clinical
features and courses. Gross-Tsur et al. described the neurological
status of 16 patients with CFC syndrome (genetically undeter-
mined cases) in their report with a literature review,4 including six
EEG ﬁndings (generalized dysrhythmia [grade, and ungraded], low
voltage, focal activity, and episodes of spike and slow 2 Hz with
slow background activity). Recently, Yoon et al. mentioned the
seizure types and EEG ﬁndings in 12 of 15 cases, including four
cases of infantile spasms with hypsarrhythmia on EEG.7 Moreover,
Aizaki et al. reported a case of CFC syndromewith infantile spasms,
suggesting that seizures with CFC syndrome were refractory
despite the administration of various types of anticonvulsants and
that the neuro-developmental delay caused by CFC syndrome is
severe.10
Both cases in the present report exhibited infantile spasmswith
severely abnormal EEG (modiﬁed hypsarrhythmia). Case 1 has
been remittedwith ACTH therapy and Case 2 remains uncontrolled
despite the administration of various types of anticonvulsants.
Upon reviewing previous literature4–10 describing the epileptic
conditions and neuroimages in patients with cardio-facio-cutane-
ous syndrome (Table 1), 62 cases were discovered which
mentioned their epileptic condition which included 12 cases
(19.3%) with infantile spasms or brief tonic spasms, each of whichwere accompanied by hypsarrhythmia or modiﬁed hypsarrhyth-
mia on EEG. Other cases also develop various types of seizures,
GTCS (sometimes evolving to status epileptics), and complex
partial seizure, with severe abnormal EEG, consisting of general-
ized or partial epileptiform activities. Most of the seizures in these
patients still remain uncontrolled despite the use of various types
of anticonvulsants. Based on the two present cases and the
literature review, the high complication rate of infantile spasms in
CFC syndrome suggests that there may be speciﬁc factors relating
to refractory epilepsy, especially epileptic encephalopathy, in the
RAS/MAPK signaling pathway.
As for correlations between genotype and epileptic phenotype,
D153V mutation in the KRAS gene (as seen in Case 1) was
previously reported11–13 in six cases (two of CFC syndrome, three
of Noonan syndrome, and one of CFC/Noonan syndrome), but in
none of these cases did the patient develop seizures. Accordingly,
this mutation may be unrelated to epileptic severity. On the other
hand, it is noteworthy that the mutation L485S in the BRAF gene
(as seen in Case 2) has been recently reported to be detected in a
patient of CFC syndrome with infantile spasms following a
refractory therapeutic course.10 This point mutation may be
related to the severity of epileptic conditions in RAS/MAPK
syndrome. In addition, this report10 described the efﬁcacy of a
ketogenic diet (KD) to reduce seizure frequency, but in the present
Case 2 patient with the same mutation in the BRAF gene, KD has
not been introduced because of severe thinness despite adequate
tube nutrition.
In a recent report of CFC patients, neuroimaging played an
important role in the diagnosis of this syndrome.14 Most of the 62
patients with CFC syndrome in the present review shared severe
abnormal neuroimaging, including hydrocephalus, agenesis/hy-
poplasia of the corpus callosum, ventricular dilatation, cortical
Table 1
Epileptic conditions and neuroimages in patients with cardio-facio-cutaneous syndrome: present cases and those from a literature review.
Ref.
Gene Mutation Sex Age of seizure
onset
Seizure type Interictal EEG ﬁndings Anticonvulsant
therpay
Seizur prognosis Neurodevelopmental
delay
Neuroimaging
(brain MRI)
Gross-Tsur
et al.4 (n=1)
N.A. N.A. M 1y 9mo Lennox–Gastaut
syndrome
Multiple episodes of spike
and slow wave activity,
2Hz. The background
activity was abnormally
slow.
VPA, CZP Decre in
seizur
Hypotonia, ataxia, lack
of language skill,
extreme hyperactivity
Normal
Raymond and
Holmes5 (n=2)
N.A. N.A. F – No seizure Decrease in anterior
voltages, no epileptiform
activity (postnatal
screening)
– – No motor delay,
marked language
delay
External
hydrocephalus
with widened
subarachnoid
space, cortical
atrophy in the
frontal and
temporal lobes (CT)
N.A. N.A. M – No seizure N.A. – – No motor delay,
marked
language delay
Marked cortical
atrophy (CT)
Sabatino
et al.6 (n=2)
N.A. N.A. M 1y 3mo Tonic-clonic (SE) Focal activity in the
bilateral posterior areas
N.A. N.A. Moderate to severe Cortical atrophy,
ventriculomegaly
N.A. N.A. F 6y GTCS Irritative waves and
generalized
disorganization, frequent
focal spikes in the right
regions, sometimes in
contralateral areas.
PB Contro ed Moderate to severe Diffuse cortical
atrophy
Yoon et al.7
(n=15)
MEK1 F53S F 15y 10mo GTCS, Abs, CPS Generalized spikes/slow
waves (n=5),
hypsarrhythmia (n=4),
focal epileptiform
discharges (n=3)
ZNS, LEV Not de ribed in
detail
Polyth apy
requir in 9 of
15 cas ,
sugge ng that
seizur ontrol is
often ﬁcult.
Severe Ventriculomegaly
and hydrocephalus
(66%), prominent
Vircho- Robin
spaces (20%),
cortical atrophy,
prominence of CFS
spaces wih
macrocephaly,
benign
extraventricular
obstructive
hydrocephalus.
(some cases)
BRAF L485F M 2wk CPS, sGTCS, Abs OXC, DZP, Severe
BRAF F468S F 11y GTCS CBZ, PB Profound
BRAF Q257R M 2y 6mo Abs, focal VPA Mild
BRAF del E11 F 1y 6mo IS TPM, CZP, VPA, PSL Severe
BRAF Q257R M 3y Not speciﬁed CBZ Severe
BRAF F595L F 6mo IS, vocal motor,
CPS
Felbamate, ZNS, CZP Profound
BRAF T599R F 3y Not speciﬁed OXC Profound
BRAF G534R M 5y GTCS, Abs OXC Profound
BRAF L485S M 4mo GTCS, CPS, IS TPM, CZP, VPA, DZP N.A.
MEK1 Y130C F 2y Not speciﬁed LEV N.A.
BRAF D638E F 1y 6mo GTCS, Abs LEV, PHT Profound
BRAF K499N F 7mo GTCS, Abs LTG, CBZ, CZP Severe
MEK1 Y130N F 1y CPS OXC Profound
MEK1 G128V F 5mo IS PB, LTG, VPA, CZP N.A.
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Table 1 (Continued )
Ref.
Gene Mutation Sex Age of seizure
onset
Seizure type Interictal EEG ﬁndings Anticonvulsant
therpay
Seizure prognosis Neurodevelopmental
delay
Neuroimaging
(brain MRI)
Armour and
Allanson8 (n=38)
BRAF
(15/32 cases)
MEK1(2/4 cases)
MEK2(1/2 cases)
N.A. N.A. IS (n=5),
Abs (n=4),
GTCS (n=4),
CPS (n=4)
N.A. N.A. Respondents 49% All signiﬁcant
delay (available
in 27cases)
Hydrocephaly (2),
ventriculomegaly (9),
reduced white matter
(6), thin corpus
callosum (3), cerebral
atrophy (3), delayed
myelination (3),
Chiari 1 malformation
(1), pachygyria (1),
nodulat heterotopia
(1), abnormal
migration (1),
cerebellar
calciﬁcation (1)
available on 23
cases)
Demir
et al.9 (n=1)
BRAF F468S F N.A. Recurrent
clonic
seizures
Epileptiform discharges
in the right front central
temporal region
VPA, CBZ, TPM Controlled Mental/motor/
language delay
Mild frontoparietal
cortical atrophy,
mildly dilated
ventricles, thinning
of the posterior
part of the
corpus callosum
Aizaki
et al.10 (n=1)
BRAF L485S F 2mo Brief tonic
spasms
(repetitive)
Asynchronous, high-
voltage slow waves with
multifocal sharp waes
appeared with bilateral
pariet-occipital
predominance
VPA, VitB6, ZNS, CLB,
PB, ACTH, KD,
Clorazepate
dipotassium
Uncontrolled Profound Hypoplastic corpus
callosum, moderate
brain atrophy,
delayed myelination,
ambiguous
coorticomedullary
boundary in the
right posterior
temporal lobe
Present cases
(n=2)
KRAS D153V M (Case 1) 3mo/11mo Myo/IS Hypsarrhythmia (at 11
mos), asynchronous, high-
voltage slow waves with
irregular spike-wave, or
polyspikes with/without
waves dominantly in the
right temporal-occipital
region (at 6 yrs)
MDL/VPA, CZP, ZNS,
ACTH
Controlled Profound Diffuse cortical
atriphy, ventricular
dulatation,
agenesis of the
corpus callosum,
delayed
myelination
BRAF L485S F (Case 2) Day 0 Subtle, brief
tonic spasms,
CPS, GTCS
Modiﬁed hypsarrhythmia
(at 1 yr), Continous high-
voltage spike or polyspikes
with/without slow waves
in the left centro-
temporalparietal region
(at 4 yrs)
MDL, VPA, CZP, NZP,
PB, CBZ, ZNS, CLB,
PHT, PRM, GAP, TPM,
LTG, LEV, TRH, ST
Uncontrolled Profound Diffuse cortical
atrophy, ventricular
dulatation,
hypoplastic corpus
callosum, delayed
myelination
GTCS: generalized tonic-clonic seizure, sGTCS: secondarily generalized tonic-clonic seizure, CPS: complex partial seizure, Abs: absence seizure, Myo: myoclonic seizure, IS: infantile spasms, SE: status epileptics, Subtle: subtle
seizure.
PB: phenobarbital, VPA: valproic acid, CBZ: carbamazepine, ZNS: zonisamide, PHT:pheytoin, PRM: primidon, CZP: clonazepam, CLB: clobazam, NZP: nitrazepam, DZP: diazepam, MDL: midazolam, ST: sultiame, VitB6: vitamin B6,
GAP: gabapentin, TPM: topiramate, LTG: lamotrigine, LEV: levetiracetam, OXC: oxcarbazepine, ACTH: adrenocorticotropic hormone, PSL: prednisone, KD: ketogenic diet, CSF: cerebrospinal ﬂuid, MRI:magnetic resonance image, CT:
computed tomography, SE: status epilepticus, N.A.: not applicable.
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M. Adachi et al. / Seizure 21 (2012) 55–6060atrophy, and delayed myeliation, resulting in neuro-developmen-
tal delay ranging from ‘moderate to severe’ to ‘profound’, all of
which distinguish CFC syndrome from the other types of RAS/
MAPK syndrome (Noonan and Costello syndromes).
More cases will need to be studied in order to clarify the
genotype–phenotype correlations of several genes in the RAS/
MAPK signaling pathway associated with refractory epilepsy.
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